Additionally, there is no data addressing outcomes in patients who do not need weight loss but are using GLP-1 agonists solely to improve metabolic health
Another widely circulating ad uses the Ministerio de Sanidad branding to imply a government-backed breakthrough in weight loss science
These products are not assessed for safety, quality, or effectiveness, and could pose serious risks to consumers
Individuals with underlying gastrointestinal conditions may experience more pronounced symptoms and should consult healthcare providers before initiating supplementation
Retrospective studies alongside pharmacovigilance reports show no significant rise in autoimmune blistering diseases among users of GLP-1RA compared to other antidiabetic drugs, implying these reactions may be unique to specific patients [43,57]
Genome-wide analysis of PPAR activation in murine small intestine